

US Dollar amounts shown in the tables below are a convenience translation of the sterling amounts. These tables are unaudited

Income statement

	H1 2024 £m	H1 2024 \$m
TURNOVER	15,247	19,301
Cost of sales	(4,092)	(5,180)
Gross profit	11,155	14,121
Selling, general and administration	(4,552)	(5,762)
Research and development	(2,911)	(3,685)
Royalty income	295	373
Other operating income/(expense)	(851)	(1,077)
OPERATING PROFIT	3,136	3,970
Finance income	56	71
Finance expense	(340)	(430)
Share of after tax profit/(loss) of associates and joint ventures	(2)	(3)
PROFIT BEFORE TAXATION	2,850	3,608
Taxation	(465)	(589)
PROFIT AFTER TAXATION FOR THE PERIOD	2,385	3,019
Profit attributable to non-controlling interests	166	210
Profit attributable to shareholders	2,219	2,809
	2,385	3,019
EARNINGS PER SHARE	54.5p	69.0c
Diluted earnings per share	53.9p	68.2c

In the income statement above US dollar results for six months period ended 30 June 2024 are calculated using average rates for six months ended 30 June 2024.

In the detailed sales tables below US dollar results for the six months ended 30 June 2024 are calculated using average rates for six months ended 30 June 2024

Vaccines turnover – six months ended 30 June 2024

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	\$m	\$m	\$m	\$m
Shingles	1,777	771	473	533	2,250	976	599	675
<i>Shingrix</i>	1,777	771	473	533	2,250	976	599	675
Meningitis	622	264	217	141	787	334	275	178
<i>Bexsero</i>	449	157	211	81	568	199	267	102
<i>Menveo</i>	164	107	4	53	207	135	5	67
Other	9	–	2	7	12	–	3	9
RSV	244	210	1	33	309	266	1	42
<i>Arexvy</i>	244	210	1	33	309	266	1	42
Influenza	20	1	(1)	20	25	1	(1)	25
<i>Fluarix, FluLaval</i>	20	1	(1)	20	25	1	(1)	25
Established Vaccines	1,613	597	356	660	2,042	756	451	835
<i>Infanrix, Pediarix</i>	239	111	60	68	303	141	76	86
<i>Boostrix</i>	321	196	69	56	406	248	87	71
<i>Hepatitis</i>	338	183	97	58	428	232	123	73
<i>Rotarix</i>	278	85	59	134	352	107	75	170
<i>Synflorix</i>	107	–	3	104	135	–	4	131
<i>Priorix, Priorix Tetra, Varilrix</i>	157	14	61	82	199	18	77	104
<i>Cervarix</i>	48	–	7	41	61	–	9	52
Other	125	8	–	117	158	10	–	148
Vaccines excluding COVID-19 solutions	4,276	1,843	1,046	1,387	5,413	2,333	1,325	1,755
Pandemic vaccines	–	–	–	–	–	–	–	–
Pandemic adjuvant	–	–	–	–	–	–	–	–
Vaccines	4,276	1,843	1,046	1,387	5,413	2,333	1,325	1,755

Specialty Medicines turnover – six months ended 30 June 2024

	Total	US	Europe	International	Total	US	Europe	International
	£m	£m	£m	£m	\$m	\$m	\$m	\$m
HIV	3,370	2,222	746	402	4,267	2,813	945	509
Dolutegravir products	2,695	1,653	663	379	3,412	2,092	840	480
<i>Tivicay</i>	672	379	130	163	851	480	165	206
<i>Triumeq</i>	656	452	120	84	830	572	152	106
<i>Juluca</i>	333	263	64	6	422	333	81	8
<i>Dovato</i>	1,034	559	349	126	1,309	707	442	160
<i>Rukobia</i>	71	67	4	–	90	85	5	–
<i>Cabenuva</i>	458	375	71	12	580	475	90	15
<i>Apretude</i>	126	123	–	3	160	156	–	4
Other	20	4	8	8	25	5	10	10
Respiratory/Immunology and Other	1,546	1,015	270	261	1,957	1,285	342	330
<i>Nucala</i>	856	467	221	168	1,084	591	280	213
<i>Benlysta</i>	678	548	57	73	858	694	72	92
Other	12	–	(8)	20	15	–	(10)	25
Oncology	629	437	161	31	796	553	204	39
<i>Zejula</i>	306	160	119	27	388	203	151	34
<i>Blenrep</i>	(2)	(3)	1	–	(3)	(4)	1	–
<i>Jemperli</i>	188	153	31	4	238	194	39	5
<i>Ojjaara/Omjjara</i>	137	127	10	–	173	160	13	–
Specialty Medicines excluding COVID 19 solutions	5,545	3,674	1,177	694	7,020	4,651	1,491	878
Pandemic	1	–	–	1	1	–	–	1
<i>Xevudy</i>	1	–	–	1	1	–	–	1
Specialty Medicines	5,546	3,674	1,177	695	7,021	4,651	1,491	879

General Medicines turnover – six months ended 30 June 2024

	Total £m	US £m	Europe £m	International £m	Total \$m	US \$m	Europe \$m	International \$m
Respiratory	3,790	2,092	717	981	4,797	2,646	909	1,242
<i>Anoro Ellipta</i>	279	125	108	46	353	158	137	58
<i>Flixotide/Flovent</i>	271	186	36	49	343	235	46	62
<i>Relvar/Breo Ellipta</i>	551	214	190	147	698	271	241	186
<i>Seretide/Advair</i>	580	212	116	252	734	268	147	319
<i>Trelegy Ellipta</i>	1,433	1,092	151	190	1,814	1,382	191	241
<i>Ventolin</i>	356	186	51	119	451	235	65	151
Other Respiratory	320	77	65	178	404	97	82	225
Other General Medicines	1,635	127	353	1,155	2,070	161	446	1,463
<i>Augmentin</i>	328	–	95	233	415	–	120	295
<i>Lamictal</i>	210	86	54	70	266	109	68	89
Other "Other General Medicines"	1,097	41	204	852	1,389	52	258	1,079
General Medicines	5,425	2,219	1,070	2,136	6,867	2,807	1,355	2,705

Commercial Operations turnover - six months ended 30 June 2024

	Total £m	US £m	Europe £m	International £m	Total \$m	US \$m	Europe \$m	International \$m
Commercial operations turnover	15,247	7,736	3,293	4,218	19,301	9,791	4,171	5,339
<i>Commercial operations turnover excluding COVID 19 solutions</i>	<i>15,246</i>	<i>7,736</i>	<i>3,293</i>	<i>4,217</i>	<i>19,300</i>	<i>9,791</i>	<i>4,171</i>	<i>5,338</i>

Balance sheet

	30 June 2024 £m	30 June 2024 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	8,982	11,367
Right of use assets	841	1,064
Goodwill	6,960	8,808
Other intangible assets	15,473	19,581
Investments in associates and joint ventures	53	67
Other investments	1,099	1,391
Deferred tax assets	6,166	7,803
Other non-current assets	1,728	2,187
Total non-current assets	41,302	52,268
Current assets		
Inventories	5,859	7,415
Current tax recoverable	519	657
Trade and other receivables	7,259	9,186
Derivative financial instruments	84	106
Liquid investments	21	27
Cash and cash equivalents	2,962	3,748
Assets held for sale	60	76
Total current assets	16,764	21,215
TOTAL ASSETS	58,066	73,483
LIABILITIES		
Current liabilities		
Short-term borrowings	(3,366)	(4,260)
Contingent consideration liabilities	(1,095)	(1,386)
Trade and other payables	(14,245)	(18,027)
Derivative financial instruments	(103)	(130)
Current tax payable	(731)	(925)
Short-term provisions	(805)	(1,019)
Total current liabilities	(20,345)	(25,747)
Non-current liabilities		
Long-term borrowings	(13,577)	(17,181)
Corporation tax payable	(104)	(132)
Deferred tax liabilities	(290)	(367)
Pensions and other post-employment benefits	(2,243)	(2,839)
Other provisions	(567)	(718)
Contingent consideration liabilities	(6,043)	(7,647)
Other non-current liabilities	(1,127)	(1,426)
Total non-current liabilities	(23,951)	(30,310)
TOTAL LIABILITIES	(44,296)	(56,057)
NET ASSETS	13,770	17,426
EQUITY		
Share capital	1,348	1,706
Share premium account	3,472	4,394
Retained earnings	8,583	10,862
Other reserves	969	1,226
Shareholders' equity	14,372	18,188
Non-controlling interests	(602)	(762)
TOTAL EQUITY	13,770	17,426

US dollar amounts shown in the balance sheet above are calculated using closing rate at 30 June 2024